HHS Moves to Allow Compounding of Unapproved Peptides Amid MAHA Push

The Department of Health and Human Services is moving to permit compounding of certain unapproved peptides, a shift that aligns with Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Again' agenda. The policy change could expand access to wellness compounds like BPC-157 and thymosin alpha-1, which are popular in alternative medicine but lack robust clinical evidence for many claimed benefits. Compounding pharmacies would gain a new market, while critics warn of safety risks and regulatory gaps. The move signals a broader embrace of peptides by federal health officials, despite ongoing debates over efficacy. This decision could reshape the supplement and compounding industries, with implications for patient safety and innovation.